Stephens & Co. Reiterates Overweight on Nurix Therapeutics, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Sudan Loganathan has reiterated an Overweight rating on Nurix Therapeutics (NASDAQ:NRIX) and maintained a $31 price target.
October 14, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stephens & Co. has reiterated its Overweight rating on Nurix Therapeutics, maintaining a $31 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and maintenance of a $31 price target by Stephens & Co. suggests a positive outlook for Nurix Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100